GlassScriptPhysician profile
Dwight L Bearden
NPI 1588737852
$675.50
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $215 · 2021: $269.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $121.64 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.31 | 2019-2021 | |
| Eisai INC. | $98.01 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $93.02 | 2019-2021 | |
| Abbvie INC. | $85.61 | 2021 | |
| Lundbeck LLC | $82.53 | 2020-2021 | |
| Adlon Therapeutics L.P. | $25.10 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $13.26 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.54 | 2019 | |
| Bausch Health US, LLC | $11.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Bearden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.